SA
FDMT

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →
11/21/26

4D Molecular Therapeutics (FDMT)

Saturday
10:46 PM ET
ThesisRecent positive clinical trial results and strategic partnerships are enhancing investor confidence in the company's growth potential.

Revenue Outlook

★ Analysts see FY2027 revenue reaching $18M — +27.2% growth in a single year.

What’s Driving the Stock

  1. 01Recent clinical trial results for lead candidate show a 75% improvement in patient outcomes compared to standard therapies.
  2. 02New partnership with a major pharmaceutical company expected to provide $50 million in upfront payments and milestone incentives.
  3. 03FDA fast track designation received for a new gene therapy targeting a rare genetic disorder.
  4. 04Increased investor interest in gene therapies as evidenced by a 30% increase in sector ETF inflows.
  5. 05Growing demand for targeted gene therapies
  6. 06Increased investment in biotechnology innovation
  7. 07Progress in clinical trials for lead gene therapy candidates, particularly for rare diseases
  8. 08Partnership announcements or expansions with major pharmaceutical companies
FY2025 Snapshot
Rev. Growth
+230195%
NI Growth
+12.9%
EPS
$-2.42

FDMT Chart

7.610.112.514.917.410.23FDMT Daily10.23Jul '26Aug '26Oct '26Nov '26

My Notes

  • "Our advancements in gene therapy are setting new standards in treatment efficacy."
  • Moat: The proprietary AAV platform provides a significant barrier to entry, but ongoing innovation is critical to maintain this advantage.
  • growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
  • Moderate - Rising interest rates could increase the cost of capital for R&D funding, potentially impacting growth plans and valuations.
  • Watch on earnings: Clinical trial success rates, Partnership revenue growth, Cash runway (months until funding is needed).

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $14M to $18M as recent clinical trial results for lead candidate show a 75% improvement in patient outcomes compared to standard.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.